EFFIENT® (PRASUGREL) EFFICACY IN STEMI-PCI PATIENTS
Greater reductions in thrombotic cardiovascular (CV) events for patients with STEMI through 15 months with Effient plus aspirin (ASA) vs clopidogrel plus ASA
PRIMARY COMPOSITE ENDPOINT
REDUCTIONS THROUGH DAY 7
REDUCTIONS THROUGH DAY 30
TRITON-TIMI 38: Primary composite endpoint in STEMI-PCI through 15 months*1,2
50% of thrombotic CV events during
the trial occurred from day 3–15
TRITON-TIMI 38: Composite endpoint in STEMI-PCI through 7 days1,4
The curves separated within the first few hours*1
TRITON-TIMI 38: Composite endpoint in STEMI-PCI through day 30*2,5
*Event curves separated within hours and were maintained through the 15‑month follow-up, but there was no progressive divergence after the first few weeks. †Relative risk reduction. ‡Absolute risk reduction. §ARR is calculated from observed data, not Kaplan-Meier rates. ‖Percentage is observed data.
In TRITON-TIMI 38, Effient provided STEMI patients early efficacy that was maintained through 15 months
- Event curves separated within hours and were maintained through the 15‑month follow-up, but there was no progressive divergence after the first few weeks1
- 50% of thrombotic CV events during the trial occurred from day 3–15 months3
- From days 0–7, 30% relative risk reduction in observed rates of the composite endpoint of CV death, nonfatal MI, or nonfatal stroke vs clopidogrel (5.5% vs 7.8%, respectively; 2.3% ARR; P=0.008)4
- Through 30 days, 32% relative risk reduction in observed rates of the secondary endpoint, a composite endpoint of CV death, nonfatal MI, or nonfatal stroke vs clopidogrel (6.5% vs 9.4%, respectively; 2.9% ARR; P=0.002)2
- Through 15 months, 21% relative risk reduction in the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke vs clopidogrel (9.8% vs 12.2%, respectively; 2.4% ARR; P=0.02)1
Important efficacy considerations
- Difference in treatments was primarily driven by a significant reduction in nonfatal MIs, with no significant difference in CV death or nonfatal stroke1
- In the overall study population, approximately 40% of MIs occurred periprocedurally and were detected solely by changes in CK-MB
Important study design consideration
- In TRITON-TIMI 38, the LD of clopidogrel was delayed relative to the placebo-controlled trials that supported its approval for ACS1
SELECTED SAFETY: EFFIENT INCREASED THE RISK OF TIMI MAJOR OR MINOR BLEEDING VS CLOPIDOGREL
Effient can cause significant, sometimes fatal, bleeding. Overall rates of non-CABG TIMI major or minor bleeding were significantly higher with Effient plus ASA (4.5%) compared with clopidogrel plus ASA (3.4%). The rates of fatal bleeding were 0.3% with Effient plus ASA and 0.1% with clopidogrel plus ASA. In patients who underwent CABG (N=437), the rates of CABG-related TIMI major or minor bleeding were 14.1% with Effient plus ASA and 4.5% with clopidogrel plus ASA.
References: 1. Effient® (prasugrel) prescribing information. Daiichi Sankyo, Inc. and Eli Lilly and Company. 2. Data on file: #EFF20080929c: DSI/Lilly. 3. Data on file: #EFF20080922a: DSI/Lilly. 4. Data on file: #EFF20130920a: DSI/Lilly. 5. Data on file: #EFF20110316a: DSI/Lilly.
Effient® (prasugrel) is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:
- Patients with unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI)
- Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI
The loading dose (LD) of Effient is 60 mg and the maintenance dose (MD) is 10 mg once daily. Effient is available in 5-mg and 10-mg tablets.
IMPORTANT SAFETY INFORMATION
WARNING: BLEEDING RISK
Effient® (prasugrel) can cause significant, sometimes fatal, bleeding.
Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke.
In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial infarction [MI]) where its effect appears to be greater and its use may be considered.
Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.
Additional risk factors for bleeding include:
- body weight <60 kg
- propensity to bleed
- concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs])
Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.
If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.
- Effient is contraindicated in patients with active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage (ICH), or a history of transient ischemic attack (TIA) or stroke, and in patients with hypersensitivity to prasugrel or any component of the product
WARNINGS AND PRECAUTIONS
- Patients who experience a stroke or TIA while on Effient generally should have therapy discontinued. Effient should also be discontinued for active bleeding and elective surgery
- Premature discontinuation of Effient increases risk of stent thrombosis, MI, and death
- Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition that can be fatal, has been reported with Effient, sometimes after a brief exposure (<2 weeks), and requires urgent treatment, including plasmapheresis
- Hypersensitivity, including angioedema, has been reported in patients receiving Effient, including patients with a history of hypersensitivity reaction to other thienopyridines
- Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction